Effect of haloperidol and risperidone on the dynamics of blood chemokine counts of the CC subfamily in patients with the first episode of schizophrenia
|
Full Text:
Subscribers Only
|
Suggested citation:
Sakharov AV, Prokhorov AS, Golygina SE, et al. [Effect of haloperidol and risperidone on the dynamics of blood chemokine counts of the CC subfamily in patients with the first episode of schizophrenia]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2025;(3):25-33. Russian
In this longitudinal prospective study, we examined the plasma levels of CC subfamily chemokines – CCL2 (MCP-1), CCL3 (MIP-1α), ССL4 (MIP-1β), CCL5 (RANTES), ССL11 (Eotaxin-1), CCL17 (TARC), CCL20 (MIP-3α) – in 80 patients with F 20.09 (“Schizophrenia paranoid, observation period less than one year”), 40 of whom received haloperidol and 40 of whom received risperidone. Before the start of therapy, the patients had increased levels of MCP-1 (CCL2) and RANTES (CCL5), decreased levels of MIP-1β (CCL4) and TARC (CCL17). This suggests a rise in the activity of neuroimmune inflammation. After 8 weeks, all antipsychotics elevated TARC (CCL17) and reduced Eotaxin-1 (CCL11), suggesting neuroplasticity enhancement and anti-inflammatory activity. Haloperidol sustained elevated MIP-1α (CCL3), while risperidone lowered MCP-1 (CCL2). As both chemokines drive neuroinflammation, risperidone demonstrates superior modulation of these pathways. Consequently, chemokines can be considered as markers of response to antipsychotic therapy in patients with schizophrenia.
Keywords schizophrenia; the first psychotic episode; biological markers; haloperidol; risperidone; chemokines; CC subfamily
1. Ermakov EA, Melamud MM, Boiko A, et al. Association of peripheral inflammatory biomarkers and growth factors levels with sex, therapy and other clinical factors in schizophrenia and patient stratification based on these data. Brain Sci. 2023;13(5):836. DOI: 10.3390/brainsci13050836 2. Klushnik TP. [In ammation as a universal pathophysiological mechanism of chronic non-communicable diseases]. Psikhiatriya [Psychiatry (Moscow)]. 2023;21(5):7–16. (In Russ.) DOI: 10.30629/2618-6667-2023-21-5-7-16 3. Prokhorov AS, Golygina SE, Sakharov AV. [Chemokines in the central nervous system, a possible pathogenetic role in schizophrenia (literature review)]. Psikhicheskoe zdorovie [Mental Health]. 2022;17(11):100–10. (In Russ.) DOI: 10.25557/2074-014X.2022.11.100-110 4. Ermakov EA, Mednova IA, Boiko AS, et al. Chemokine dysregulation and neuroinflammation in schizophrenia: a systematic review. Int J Mol Sci. 2023;24(3):2215. DOI: 10.3390/ijms24032215 5. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity. 2000;12(2):121–7. DOI: 10.1016/s1074-7613(00)80165-x 6. Ge S, Song L, Serwanski DR, et al. Transcellular transport of CCL2 across brain microvascular endothelial cells. J Neurochem. 2008;104(5):1219–32. DOI: 10.1111/j.1471-4159.2007.05056.x 7. Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Parsadaniantz SM. Current status of chemokines in the adult CNS. Prog Neurobiol. 2013;104:67–92. DOI: 10.1016/j.pneurobio.2013.02.001 8. Klaus F, Mitchell K, Liou SC, et al. Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: A preliminary analysis. J Psychiatr Res. 2021;138:139–45. DOI: 10.1016/j.jpsychires.2021.04.007 9. Sakharov AV, Minduskin IV, Golygina SE. [Prognostic role of neuromarkers in the first episode of paranoid schizophrenia before therapy]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2023;(2):38–45. (In Russ.) 10. Zhu X, Wei D, Chen O, et al. Upregulation of CCL3/MIP-1alpha regulated by MAPKs and NF-kappaB mediates microglial inflammatory response in LPS-induced brain injury. Acta Neurobiol Exp (Wars). 2016;76(4):304–17. DOI: 10.21307/ane-2017-029 11. Quaranta DV, Weaver RR, Baumann KK, et al. Transport of the proinflammatory chemokines CC motif chemokine ligand 2 (MCP-1) and CC motif chemokine ligand 5 (RANTES) across the intact mouse blood-brain barrier is inhibited by heparin and eprodisate and increased with systemic inflammation. J Pharmacol Exp Ther. 2023;384(1):205–23. DOI: 10.1124/jpet.122.001380 12. Radzik T, Boczek T, Ferenc B, et al. Calcium Dyshomeostasis Alters CCL5 signaling in differentiated PC12 cells. Biomed Res Int. 2019;2019:9616248. DOI: 10.1155/2019/9616248 13. Khavinson VK, Kuznik BI, Ryzhak GA, et al. [“Protein of senility” CCL11, “protein of juvenility” GDF11 and their role in age-related pathology]. Uspekhi gerontologii [Adv Gerontol]. 2016;29(5):722–31. (In Russ.) 14. Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the role of eotaxin-1/CCL11 in psychiatric disorders. Front Psychiatry. 2018;9:241. DOI: 10.3389/fpsyt.2018.00241 15. Zhang A, Liu Y, Xu H, et al. CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats. Stroke Vasc Neurol. 2023;8(1):4–16. DOI: 10.1136/svn-2022-001659 16. Hong S, Lee EE, Martin AS, et al. Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Schizophr Res. 2017;181:63–9. DOI: 10.1016/j.schres.2016.09.019 17. Malmqvist A, Schwieler L, Orhan F, et al. Increased peripheral levels of TARC/CCL17 in first episode psychosis patients. Schizophr Res. 2019;210:221–7. DOI: 10.1016/j.schres.2018.12.033 18. Rothhammer V, Quintana FJ. Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol. 2015;37(6):625–38. DOI: 10.1007/s00281-015-0515-3 19. Akkouh IA, Ueland T, Hansson L, et al. Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: Potential attenuating effects on recruitment of regulatory T cells. Brain Behav Immun. 2020;87:634–44. DOI: 10.1016/j.bbi.2020.02.008 20. Yuhas Y, Ashkenazi S, Berent E, Weizman A. Clozapine suppresses the gene expression and the production of cytokines and up-regulates cyclooxygenase 2 mRNA in human astroglial cells. Brain Sci. 2022;12(12):1703. DOI: 10.3390/brainsci12121703 21. Prokhorov AS, Golygina SE, Sakharov AV. [Prognostic value of chemokines in the first episode of paranoid schizophrenia before the start of antipsychotic therapy]. Sibirskii vestnik psikhiatrii i narkologii [Siberian Herald of Psychiatry and Addiction Psychiatry]. 2024;4(125):5–16. (In Russ.) DOI: 10.26617/1810-3111-2024-4(125)-5-16 22. Frydecka D, Krzystek-Korpacka M, Lubeiro A, et al. Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. Brain Behav Immun. 2018;71:28–36. DOI: 10.1016/j.bbi.2018.05.002 23. Drzyzga Ł, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006;20(6):532–45. DOI: 10.1016/j.bbi.2006.02.002
Article Metrics
Metrics powered by PLOS ALM